Other kidney cancer research included an 8-gene panel that was able to predict high tumor grade in biopsy specimens and a review of perioperative transfusion’s effect on recurrence-free and overall survival.
Jodi K. Maranchie, MDOther kidney cancer research included an examination of metastasectomy trends in the National Cancer Database and a review of perioperative transfusion's effect on recurrence-free and overall survival. The kidney cancer take-home messages were presented by Jodi K. Maranchie, MD, of the University of Pittsburgh School of Medicine.
In 260 patients, intrahepatic fat, as measured by preoperative computed tomography scan, was an independent predictor of overall and cancer-specific survival irrespective of visceral obesity.
Immunosuppressive M2 macrophage infiltration in the tumor microenvironment is associated with significantly worse cancer-specific survival in clear cell renal cell carcinoma patients.
An 8-gene panel based on the Cancer Genome Atlas project was able to predict high tumor grade in preoperative biopsy specimens and will hopefully improve the accuracy of renal biopsies.
An examination of metastasectomy trends in the National Cancer Database showed improved survival in patients undergoing metastasectomy and chemotherapy compared to chemotherapy alone. Despite this, rates of metastasectomy have been dropping in recent years, suggesting potential undertreatment in this population. In a parallel study looking at more than 13,000 metastatic kidney cancer patients, improved survival was seen following cytoreductive nephrectomy, with a difference of 16.8 months versus 8 months and a hazard ratio of 0.4. Even in the targeted therapy era, it appears that cytoreductive nephrectomy is protective.
Not all chromatin modeling mutations are created equally. In 194 patients with clear cell renal cancer, the presence of only a PBRM1 mutation actually improved survival relative to those with neither mutation. In contrast, the presence of the BAP1 mutation with or without concomitant PBRM1 conferred dismal survival, dropping from a mean of 40 to 18 months.
Subscribe to Urology Times to get monthly news from the leading news source for urologists.